WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

starting with: CRYSTAL$8(CRYSTAL/MAUNT).P28-P87,P89-P89,P23-P27,P20-P22,P1-P18.

Search Results -

Terms	Documents
l8 same (x-ray or crystal$8 or atomic coordinate$2)	1

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search: `l8 same (x-ray or crystal$8 or atomic coordinate$2)` Clear

Search History

Today's Date: 8/22/2001

DB Name	Query	Hit Count	Set Name
USPT,PGPB,JPAB,EPAB,DWPI	l8 same (x-ray or crystal$8 or atomic coordinate$2)	1	L10
USPT,PGPB,JPAB,EPAB,DWPI	l8 and (x-ray or crystal$10 or atomic coordinate$2)	53	L9
USPT,PGPB,JPAB,EPAB,DWPI	l4 or l5	237	L8
USPT,PGPB	l3 and l4	2	L7
JPAB,EPAB,DWPI	l3 and l4	0	L6
JPAB,EPAB,DWPI	human same phospholipase a2	132	L5
USPT,PGPB	human same phospholipase a2	105	L4
USPT,PGPB	l1 or l2	948	L3
USPT,PGPB	((702/19)!.CCLS.)	201	L2
USPT,PGPB	((435/18)!.CCLS. \|(19/)!.CCLS.)	748	L1

WEST

Generate Collection

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 6242206 B1

L7: Entry 1 of 2 File: USPT Jun 5, 2001

US-PAT-NO: 6242206
DOCUMENT-IDENTIFIER: US 6242206 B1

TITLE: Human phospholipase A2 and related nucleic acid compounds

DATE-ISSUED: June 5, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Choiu; Xue-Chiou C.	Lake Bluff	IL	N/A	N/A
Kramer; Ruth M.	Indianapolis	IN	N/A	N/A
Pickard; Richard T.	Noblesville	IN	N/A	N/A
Sharp; John D.	Arlington	MA	N/A	N/A
Strifler; Beth A.	Brownsburg	IN	N/A	N/A

US-CL-CURRENT: 435/18; 435/198, 435/252.3, 435/320.1, 435/69.2, 530/350, 536/23.2

ABSTRACT:

The invention provides a novel phospholipase A.sub.2 enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

2 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 5707821 A

L7: Entry 2 of 2 File: USPT Jan 13, 1998

US-PAT-NO: 5707821
DOCUMENT-IDENTIFIER: US 5707821 A

TITLE: Identification of phospholipase A2 inhibitors in A.beta. peptide-mediated neurodegenerative disease

DATE-ISSUED: January 13, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rydel; Russell E.	Belmont	CA	N/A	N/A
Dappen; Michael S.	San Bruno	CA	N/A	N/A

US-CL-CURRENT: 435/18; 435/4, 514/12

ABSTRACT:

The invention provides methods and compositions for treating neurodegeneration in mammalian cells by administering a phospholipase A2 inhibitor.

7 Claims, 12 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 9

WEST

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Generate Collection

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: HU 200000292 A2, EP 846687 A1, WO 9824437 A1, AU 9853655 A, ZA 9710878 A, US 5972972 A, BR 9713993 A, MX 9905167 A1, KR 2000057366 A

L10: Entry 1 of 1 File: DWPI Apr 28, 2001

DERWENT-ACC-NO: 1998-299930
DERWENT-WEEK: 200131
COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: New pyrazole derivatives used to treat e.g. septic shock - are human non-pancreatic secretory phospholipase A2 inhibitors, and inhibit mediated release of fatty acids and arachidonic acid cascade

INVENTOR: DOMAN, P J; HITE, G A ; MIHELICH, E D ; SUAREZ, T ; WILLETTS, S E ; MICHELICH, E D

PRIORITY-DATA: 1996US-0033216 (December 4, 1996), 1997US-0984261 (December 3, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
HU 200000292 A2	April 28, 2001	N/A	000	A61K031/495
EP 846687 A1	June 10, 1998	E	044	C07D231/44
WO 9824437 A1	June 11, 1998	E	000	A61K031/495
AU 9853655 A	June 29, 1998	N/A	000	A61K031/495
ZA 9710878 A	August 31, 1999	N/A	078	C07D000/00
US 5972972 A	October 26, 1999	N/A	000	C07D401/04
BR 9713993 A	February 8, 2000	N/A	000	A61K031/495
MX 9905167 A1	October 1, 1999	N/A	000	A61K031/495
KR 2000057366 A	September 15, 2000	N/A	000	C07D231/00

INT-CL (IPC): A61K 31/415; A61K 31/44; A61K 31/47; A61K 31/495; A61K 31/50; A61P 37/00; C07D 0/00; C07D 231/00; C07D 231/44; C07D 231/52; C07D 401/04; C07D 401/14; C07D 403/00; C07D 403/04; C07D 405/00; C07D 409/00; C07D 409/12; C07D 409/14; C07D 417/14; C07D 213/00; C07D 401/04

ABSTRACTED-PUB-NO: EP 846687A
BASIC-ABSTRACT:

Pyrazole derivatives of formula (I) and their salts are new: R1 = Ph, isoquinolin-3-yl, pyrazinyl, pyridin-2-yl (optionally 4-substituted by 1-4C alkyl, 1-4C alkoxy, CN or (CH2)nCONH2; n = 0-2; R2 = Ph (optionally substituted by 1-3 1-4C alkyl, CN, halo, NO2, CO2(1-4C) alkyl or CF3), naphthyl or thiophene (optionally substituted by 1-3 halo); R3 = H, Ph, phenyl(2-6C) alkenyl, pyridyl, naphthyl, quinolinyl, 1-4C alkylthioazolyl or Ph (optionally substituted by 1-2 1-4C alkyl, CN, CONH2, NO2, CF3, halo, 1-4C alkoxy, CO2(1-4C) alkyl, OPh or SR4 or by one O(CH2)pR5, Ph or OR6, or by two substituents which form methylene dioxy; R4 = 1-4C alkyl or halophenyl; p = 1-3; R5 = CN, COOH, CONH2 or tetrazolyl; R6 =

cyclopentyl, cyclohexenyl or Ph (substituted by halo or 1-4C alkoxy); and m = 1-5.

USE - (I) are human non-pancreatic secretory phospholipase A2 inhibitors (sPLA2) and are useful for alleviating the pathological effects of septic shock, adult respiratory syndrome (ARDS), pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, rheumatoid arthritis, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondylarthropathies, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enterapathric spondylitis, Juvenile arthropathy or juvenile ankylosing spondylitis, Reactive arthropathy, infectious or post-infections arthritis, gonoccocal arthritis, Tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with vasculitic syndrome, polyarteritis nodosa, hypersensitivity vasculitis, Luegenec's granulomatosis, polymyalgia, rheumatica, joint cell arteritis, calcium crystal deposition arthropathies, pseudo gout, non-articular rheumatism, bursitis, tenosynomitis, epicondylitis, carpal tunnel syndrome, repetitive use injury, miscellaneous forms of arthritis, neuropathic joint disease, haemarthrosis, Henoch-Schonlein Purpura, hypertrophic osteoarthropathy, multicentre reticulohistocytosis, arthritis associated with certain diseases, surcoilosis, haemochromatosis, sickle cell disease and other haemoglobinopathies, hyperlipoproteinaemia, hypogammaglobulinaemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behat's disease, systemic lupus erythematosis or relapsing polychondritis (claimed). (I) inhibit sPLA2 mediated release of fatty acids and inhibits or prevents arachidonic acid cascade and its deleterious products.
ABSTRACTED-PUB-NO:

US 5972972A EQUIVALENT-ABSTRACTS:

Pyrazole derivatives of formula (I) and their salts are new: R1 = Ph, isoquinolin-3-yl, pyrazinyl, pyridin-2-yl (optionally 4-substituted by 1-4C alkyl, 1-4C alkoxy, CN or (CH2)nCONH2; n = 0-2; R2 = Ph (optionally substituted by 1-3 1-4C alkyl, CN, halo, NO2, CO2(1-4C) alkyl or CF3), naphthyl or thiophene (optionally substituted by 1-3 halo); R3 = H, Ph, phenyl(2-6C) alkenyl, pyridyl, naphthyl, quinolinyl, 1-4C alkylthioazolyl or Ph (optionally substituted by 1-2 1-4C alkyl, CN, CONH2, NO2, CF3, halo, 1-4C alkoxy, CO2(1-4C) alkyl, OPh or SR4 or by one O(CH2)pR5, Ph or OR6, or by two substituents which form methylene dioxy; R4 = 1-4C alkyl or halophenyl; p = 1-3; R5 = CN, COOH, CONH2 or tetrazolyl; R6 = cyclopentyl, cyclohexenyl or Ph (substituted by halo or 1-4C alkoxy); and m = 1-5.

USE - (I) are human non-pancreatic secretory phospholipase A2 inhibitors (sPLA2) and are useful for alleviating the pathological effects of septic shock, adult respiratory syndrome (ARDS), pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, rheumatoid arthritis, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondylarthropathies, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enterapathric spondylitis, Juvenile arthropathy or juvenile ankylosing spondylitis, Reactive arthropathy, infectious or post-infections arthritis, gonoccocal arthritis, Tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with vasculitic syndrome, polyarteritis nodosa, hypersensitivity vasculitis, Luegenec's granulomatosis, polymyalgia, rheumatica, joint cell arteritis, calcium crystal deposition arthropathies, pseudo gout, non-articular rheumatism, bursitis, tenosynomitis, epicondylitis, carpal tunnel syndrome, repetitive use injury, miscellaneous forms of arthritis, neuropathic joint disease, haemarthrosis, Henoch-Schonlein Purpura, hypertrophic osteoarthropathy, multicentre reticulohistocytosis, arthritis associated with certain diseases, surcoilosis, haemochromatosis, sickle cell disease and other haemoglobinopathies, hyperlipoproteinaemia, hypogammaglobulinaemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behat's disease, systemic lupus erythematosis or relapsing polychondritis (claimed). (I) inhibit sPLA2 mediated release of fatty acids and inhibits or prevents arachidonic acid cascade and its deleterious products.

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw Desc | Clip Img | Image

WEST

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Generate Collection

Search Results - Record(s) 1 through 10 of 53 returned.

☐ 1. Document ID: US 20010007666 A1

L9: Entry 1 of 53 File: PGPB Jul 12, 2001

PGPUB-DOCUMENT-NUMBER: 20010007666
PGPUB-FILING-TYPE: new-utility
DOCUMENT-IDENTIFIER: US 20010007666 A1

TITLE: ENHANCED TRANSPORT USING MEMBRANE DISRUPTIVE AGENTS

PUBLICATION-DATE: July 12, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
HOFFMAN, ALLAN S.	SEATTLE	WA	US	
STAYTON, PATRICK	SEATTLE	WA	US	
PRESS, OLIVER W.	SEATTLE	WA	US	
TIRRELL, DAVID	PASADENA	CA	US	
MURTHY, NIREN	SEATTLE	WA	US	
LACKEY, CHANTAL	SEATTLE	WA	US	
CRUM, LAWRENCE A.	ISSAQUAH	WA	US	
MOURAD, PIERRE D.	SEATTLE	WA	US	
PORTER, TYRONE M.	SEATTLE	WA	US	

US-CL-CURRENT: 424/400

ABSTRACT:

Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontopheresis, and/or electrophereis can also be used with the disrupting agents.

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 2. Document ID: US 6270964 B1

L9: Entry 2 of 53 File: USPT Aug 7, 2001

US-PAT-NO: 6270964
DOCUMENT-IDENTIFIER: US 6270964 B1

TITLE: Protein fragment complementation assays for the detection of biological or drug interactions

DATE-ISSUED: August 7, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Michnick; Stephen William Watson	Westmount	N/A	N/A	CAX
Pelletier; Joelle Nina	Westmount	N/A	N/A	CAX
Remy; Ingrid	Montreal	N/A	N/A	CAX

US-CL-CURRENT: 435/6; 435/243, 435/325, 435/410, 435/69.7, 530/350, 536/23.1, 536/23.4

ABSTRACT:

We describe a strategy for designing and implementing protein-fragment complementation assays (PCAs) to detect biomolecular interactions in vivo and in vitro. The design, implementation and broad applications of this strategy are illustrated with a large number of enzymes with particular detail provided for the example of murine dihydrofolate reductase (DHFR). Fusion peptides consisting of N- and C-terminal fragments of murine DHFR fused to GCN4 leucine zipper sequences were coexpressed in Escherichia coli grown in minimal medium, where the endogenous DHFR activity was inhibited with trimethoprim. Coexpression of the complementary fusion products restored colony formation. Survival only occurred when both DHFR fragments were present and contained leucine-zipper forming sequences, demonstrating that reconstitution of enzyme activity requires assistance of leucine zipper formation. DHFR fragment-interface point mutants of increasing severity (Ile to Val, Ala and Gly) resulted in a sequential increase in E. coli doubling times illustrating the successful DHFR fragment reassembly rather than non-specific interactions between fragments. This assay could be used to study equilibrium and kinetic aspects of molecular interactions including protein-protein, protein-DNA, protein-RNA, protein-carbohydrate and protein-small molecule interactions, for screening cDNA libraries for binding of a target protein with unknown proteins or libraries of small organic molecules for biological activity. The selection and design criteria applied here is developed for numerous examples of clonal selection, colorometric, fluorometric and other assays based on enzymes whose products can be measured. The development of such assay systems is shown to be simple, and provides for a diverse set of protein fragment complementation applications.

41 Claims, 9 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 3. Document ID: US 6268135 B1

L9: Entry 3 of 53 File: USPT Jul 31, 2001

US-PAT-NO: 6268135
DOCUMENT-IDENTIFIER: US 6268135 B1

TITLE: Phospholipase molecule and uses therefor

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Acton; Susan	Lexington	MA	N/A	N/A

US-CL-CURRENT: 435/6; 435/198, 435/21, 435/252.3, 435/320.1, 530/350, 536/23.2, 536/23.5

ABSTRACT:

Novel CSAPL polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length CSAPL proteins, the invention further provides isolated CSAPL fusion proteins, antigenic peptides and anti-CSAPL antibodies. The invention also provides CSAPL nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CSAPL gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

14 Claims, 3 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 3

☐ 4. Document ID: US 6267962 B1

L9: Entry 4 of 53 File: USPT Jul 31, 2001

US-PAT-NO: 6267962
DOCUMENT-IDENTIFIER: US 6267962 B1

TITLE: Compositions and methods of treatment using peat derivatives

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hart; Ralph M.	Lake Forest Park	WA	N/A	N/A
Jones; Herman L.	Wenatchee	WA	N/A	N/A
Jones; Veronica Lee Egelkrout	Wenatchee	WA	N/A	N/A
Malik; Sohail	Redmond	WA	N/A	N/A
Kenny; Margaret A.	Edmonds	WA	N/A	N/A
Loev; Bernard	Medford	NJ	N/A	N/A
Harnisch; James P.	Mercer Island	WA	N/A	N/A

US-CL-CURRENT: 423/155, 423/158, 423/166, 423/179, 423/184, 423/193, 514/686, 514/825, 514/858, 514/861, 514/863, 514/886

ABSTRACT:

Novel compositions containing at least one biologically active component derived from peat or similar composition, methods for their preparation and therapeutic uses for a variety of diseases, injuries, and conditions, including wound healing, pain, itch, inflammation, abnormal cell proliferation, or infections caused by fungal, bacterial, rickettsial or viral agents, psoriasis, allergic and other dermatitis, pruritis, eczema, actinic keratosis and similar conditions. In addition, the compositions can be used as diuretics, antiarrhythmics, and cardiac-stimulating agents, as well as for the treatment of mammalian diseases and disorders, including multiple drug resistance, cancers, asthma, rheumatoid arthritis, pain, wound healing, fungal disorders, and other inflammatory disorders. The compositions are derivable from peat or peat-related substances and may alternatively be synthetically produced.

26 Claims, 7 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw. Desc | Image

☐ 5. Document ID: US 6265591 B1

L9: Entry 5 of 53 File: USPT Jul 24, 2001

US-PAT-NO: 6265591
DOCUMENT-IDENTIFIER: US 6265591 B1

TITLE: Process for preparing 4-substituted-1h-indole-3-glyoxamides

DATE-ISSUED: July 24, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Anderson; Benjamin Alan	Zionsville	IN	N/A	N/A
Harn; Nancy Kay	Indianapolis	IN	N/A	N/A

US-CL-CURRENT: 548/486; 548/491, 548/493, 548/494, 548/495

ABSTRACT:

A process for preparing 1H-indole-3-glyoxamides useful for inhibiting SPLA.sub.2 and novel intermediates useful in the preparation of such compounds.

4 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 6. Document ID: US 6262023 B1

L9: Entry 6 of 53 File: USPT Jul 17, 2001

US-PAT-NO: 6262023
DOCUMENT-IDENTIFIER: US 6262023 B1

TITLE: WD-40 derived peptides and uses thereof

DATE-ISSUED: July 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mochly-Rosen; Daria	Menlo Park	CA	N/A	N/A
Ron; Dorit	San Francisco	CA	N/A	N/A

US-CL-CURRENT: 514/12; 435/194, 530/300, 530/324

ABSTRACT:

The present invention relates to a polypeptide composition effective to alter the activity of a first protein that interacts with a second protein, where the second protein contains at least one WD-40 region. The polypeptides of the present invention typically have between 4 and 50 amino acids whose sequence is the same as a sequence of the same length in the WD-40 region of the second protein. The invention further includes a method of altering the activity of the above described first protein. In one embodiment of the invention the polypeptide composition is effective to alter the activity of a protein kinase C, where the protein kinase C interacts with a second protein, and the second protein contains at least one WD-40 region (e.g., RACK1).

8 Claims, 55 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 54

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 7. Document ID: US 6258600 B1

L9: Entry 7 of 53 File: USPT Jul 10, 2001

US-PAT-NO: 6258600
DOCUMENT-IDENTIFIER: US 6258600 B1

TITLE: Antisense modulation of caspase 8 expression

DATE-ISSUED: July 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zhang; Hong	Carlsbad	CA	N/A	N/A
Cowsert; Lex M.	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 435/366; 435/183, 435/212, 435/325, 435/375, 536/23.1, 536/24.3, 536/24.31, 536/24.5

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of caspase 8. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding caspase 8. Methods of using these compounds for modulation of caspase 8 expression and for treatment of diseases associated with expression of caspase 8 are provided.

13 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 8. Document ID: US 6255281 B1

L9: Entry 8 of 53 File: USPT Jul 3, 2001

US-PAT-NO: 6255281
DOCUMENT-IDENTIFIER: US 6255281 B1

TITLE: Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions

DATE-ISSUED: July 3, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pilon; Aprile L.	Gaithersburg	MD	N/A	N/A
Mukherjee; Anil B.	Brookeville	MD	N/A	N/A
Zhang; Zhongjian	Rockville	MD	N/A	N/A

US-CL-CURRENT: 514/12; 514/2, 530/300, 530/836, 530/848, 530/850, 930/250

ABSTRACT:

Method for treatment of inflammatory and fibrotic conditions in vivo using pure rhUG is disclosed. Method for treating or preventing inflammatory or fibrotic conditions characterized by a deficiency of endogenous functional UG is also disclosed. Compositions containing pure rhUG, optionally also containing lung surfactant, and assay procedures for detection of UG-fibronectin complexes, are also provided.

10 Claims, 35 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw Desc | Image

☐ 9. Document ID: US 6252084 B1

L9: Entry 9 of 53 File: USPT Jun 26, 2001

US-PAT-NO: 6252084
DOCUMENT-IDENTIFIER: US 6252084 B1

TITLE: 1H-indole-3-acetamide sPLA2 inhibitors

DATE-ISSUED: June 26, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bach; Nicholas J.	Indianapolis	IN	N/A	N/A
Dillard; Robert D.	Zionsville	IN	N/A	N/A
Draheim; Susan E.	Indianapolis	IN	N/A	N/A
Hermann; Robert B.	Indianapolis	IN	N/A	N/A
Schevitz; Richard W.	Indianapolis	IN	N/A	N/A

US-CL-CURRENT: 548/113; 548/127, 548/252, 548/253, 548/254, 548/483, 548/494, 548/495, 548/496

ABSTRACT:

A class of novel 1H-indole-3-acetamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

2 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 10. Document ID: US 6239285 B1

L9: Entry 10 of 53 File: USPT May 29, 2001

US-PAT-NO: 6239285
DOCUMENT-IDENTIFIER: US 6239285 B1

TITLE: Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems

DATE-ISSUED: May 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Norris; Timothy	Gales Ferry	CT	N/A	N/A
Hnatow; Megan E.	Charlestown	MA	N/A	N/A

US-CL-CURRENT: 548/304.7; 548/311.1, 548/362.5, 548/365.7

ABSTRACT:

A process is described for preparing a compound of Formula (1.3.0): ##STR1##

comprising: establishing a reaction mixture consisting of ##STR2##

in an aprotic solvent; in the presence of NaOH or KOH; optionally in the presence of a phase transfer catalyst, especially a quaternary ammonium salt or a phosphonium salt; followed by heating said reaction mixture under a nitrogen atmosphere.

1 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

Generate Collection

Terms	Documents
l8 and (x-ray or crystal$10 or atomic coordinate$2)	53

Display 10 Documents, starting with Document: 11

Display Format: REV Change Format

WEST

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Generate Collection

Search Results - Record(s) 11 through 20 of 53 returned.

☐ 11. Document ID: US 6218437 B1

L9: Entry 11 of 53 File: USPT Apr 17, 2001

US-PAT-NO: 6218437
DOCUMENT-IDENTIFIER: US 6218437 B1

TITLE: Treatment and prevention of hepatic disorders

DATE-ISSUED: April 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chojkier; Mario	San Diego	CA	N/A	N/A

US-CL-CURRENT: 514/731; 514/567, 562/433, 562/454, 568/716

ABSTRACT:

The present invention provides new methods for the treatment of viral hepatitis C involving the administration of vitamin E and other compounds with antioxidant properties. Treatment with high doses of vitamin E is effective in treating chronic hepatitis C in patients refractory to interferon. In addition, new methods are described for the treatment of hepatic fibrosis and hepatic conditions manifesting hepatic fibrosis involving the administration of butylated hydroxytoluene and a metabolite of pentoxifylline, 1-[3-carboxypropyl]-3, 7-dimethylxanthine. Furthermore, new methods are described for the treatment and prevention of hepatic disorders involving the use of 2,6-di-tert-butylphenol derivatives.

8 Claims, 22 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw. Desc | Image

☐ 12. Document ID: US 6197965 B1

L9: Entry 12 of 53 File: USPT Mar 6, 2001

US-PAT-NO: 6197965
DOCUMENT-IDENTIFIER: US 6197965 B1

TITLE: Compounds having a plurality of nitrogenous substituents

DATE-ISSUED: March 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cook; P. Dan	Vista	CA	N/A	N/A
An; Haoyun	Encinitas	CA	N/A	N/A

US-CL-CURRENT: 546/334; 546/271.4, 546/272.4, 546/278.1

ABSTRACT:

Novel compounds are constructed to include a central aromatic, aliphatic, or heterocyclic ring system. Attached to the central ring system are two linear groups having nitrogenous moieties that are derivatized with chemical functional groups. The ring system can include further nitrogenous moieties, either as ring atoms or on pendant groups attached to the ring, that may also be derivatized with chemical functional groups. The totality of the chemical functional groups imparts certain conformational and other properties to the these compounds. In accordance with certain embodiments of the invention, libraries of such compounds are prepared utilizing permutations and combinations of the chemical functional groups and the nitrogenous moieties to build complexity into the libraries.

9 Claims, 10 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw Desc | Image

☐ 13. Document ID: US 6191273 B1

L9: Entry 13 of 53 File: USPT Feb 20, 2001

US-PAT-NO: 6191273
DOCUMENT-IDENTIFIER: US 6191273 B1

TITLE: Substituted cyclic compounds and mixtures comprising same

DATE-ISSUED: February 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cook; Phillip Dan	Lake San Marcos	CA	N/A	N/A
An; Haoyun	Encinitas	CA	N/A	N/A
Haly; Becky	La Mesa	CA	N/A	N/A
Wang; Tingmin	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 540/472

ABSTRACT:

Novel chemical compounds and mixtures of same are provided having antibacterial and other utilities. The mixtures preferably are formed by reacting a cyclic scaffold moiety with a set of chemical substituients. Libraries formed in accordance with the invention have utility per se and are articles of commerce. They can be used to screen for pesticides, drugs and other biologically active compounds.

3 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw. Desc | Image

☐ 14. Document ID: US 6187533 B1

L9: Entry 14 of 53 File: USPT Feb 13, 2001

US-PAT-NO: 6187533
DOCUMENT-IDENTIFIER: US 6187533 B1

TITLE: Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (HNF) 1 alpha (.alpha.), HNF1.beta. and HNF4.alpha.

DATE-ISSUED: February 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bell; Graeme I.	Chicago	IL	N/A	N/A
Yamagata; Kazuya	Kaizuka	N/A	N/A	JPX
Oda; Naohisha	Chicago	IL	N/A	N/A
Kaisaki; Pamela J.	Headington	N/A	N/A	GBX
Furuta; Hiroto	Wakayama	N/A	N/A	JPX
Horikawa; Yukio	Chicago	IL	N/A	N/A
Menzel; Stephan	Headington	N/A	N/A	GBX

US-CL-CURRENT: 435/6; 435/91.2

ABSTRACT:

The present invention relates generally to the fields diabetes. More particularly, it concerns the identification of genes responsible for NIDDM for use in diagnostics and therapeutics. The present invention demonstrates that the MODY3 locus is, in fact, the HNF1.alpha. gene, MODY4 locus is the HNF1.beta. and the MODY1 locus is the HNF4.alpha. gene. The invention further relates to the discovery that analysis of mutations in the HNF1.alpha., HNF1.beta. and HNF4.alpha. genes can be diagnostic for diabetes. The invention also contemplates methods of treating diabetes in view of the fact that HNF1.alpha., HNF1.beta. and HNF4.alpha. mutations can cause diabetes.

16 Claims, 163 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 147

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw. Desc | Image

☐ 15. Document ID: US 6175021 B1

L9: Entry 15 of 53 File: USPT Jan 16, 2001

US-PAT-NO: 6175021
DOCUMENT-IDENTIFIER: US 6175021 B1

TITLE: 1H-indole-3-glyoxylamide sPLA2 inhibitors

DATE-ISSUED: January 16, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bach; Nicholas J.	Indianapolis	IN	N/A	N/A
Dillard; Robert D.	Zionsville	IN	N/A	N/A
Draheim; Susan E.	Indianapolis	IN	N/A	N/A

US-CL-CURRENT: 548/493; 548/495

ABSTRACT:

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

2 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 16. Document ID: US 6166062 A

L9: Entry 16 of 53 File: USPT Dec 26, 2000

US-PAT-NO: 6166062
DOCUMENT-IDENTIFIER: US 6166062 A

TITLE: Pharmaceutical compositions containing phospholipase inhibitor

DATE-ISSUED: December 26, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Confer; William Lester	Indianapolis	IN	N/A	N/A
Tai; Hideaki	Osaka	N/A	N/A	JPX

US-CL-CURRENT: 514/419; 514/415

ABSTRACT:

A lyophilized pharmaceutical composition is described which contains Sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1H-indol-4-yl]oxy]ace tate, a Solubilizer, and a Stabilizer. Such compositions are storage stable and readily dissolve in aqueous medium to give injectable solution for treatment of sepsis, etc.

24 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 17. Document ID: US 6121433 A

L9: Entry 17 of 53 File: USPT Sep 19, 2000

US-PAT-NO: 6121433
DOCUMENT-IDENTIFIER: US 6121433 A

TITLE: Oligomeric compounds having nitrogen-containing linkages

DATE-ISSUED: September 19, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cook; Phillip Dan	Vista	CA	N/A	N/A
Sanghvi; Yogesh S.	San Marcos	CA	N/A	N/A
Kung; Pei Pei	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 536/22.1; 536/18.7, 536/24.3, 536/24.31, 536/24.32, 536/24.5, 585/500

ABSTRACT:

Novel compounds and libraries of compounds based on nitrogen atoms that are joined together with spanner groups include "letters" i.e., functional groups, that are attached to the nitrogen atoms, to the spanner groups or to both the nitrogen atoms and the spanner groups to render the compounds and libraries of such compounds with diverse properties.

13 Claims, 14 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 14

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Drawi Desc | Image

☐ 18. Document ID: US 6117977 A

L9: Entry 18 of 53 File: USPT Sep 12, 2000

US-PAT-NO: 6117977
DOCUMENT-IDENTIFIER: US 6117977 A

TITLE: Type C lectins

DATE-ISSUED: September 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lasky; Laurence A.	Sausalito	CA	N/A	N/A
Wu; Kai	San Bruno	CA	N/A	N/A

US-CL-CURRENT: 530/350; 435/252.3, 435/320.1, 435/69.1, 536/23.1

ABSTRACT:

The invention concerns novel members of the endocytic type C lectin family and methods and means for producing them. The native polypeptides of the invention are characterized by containing a signal sequence, a cysteine rich domain, a fibronectin type II domain, 8 type C lectin domains, a transmembrane domain and a cytoplasmic domain. Nucleotide sequences encoding such polypeptides, vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel type C lectins are also within the scope of the invention.

34 Claims, 19 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 24

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

19. Document ID: US 6113897 A

L9: Entry 19 of 53 File: USPT Sep 5, 2000

US-PAT-NO: 6113897
DOCUMENT-IDENTIFIER: US 6113897 A

TITLE: Antibodies and their use

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dan.o slashed.; Keld	Charlottenlund	N/A	N/A	DKX
R.o slashed.nne; Ebbe	Copenhagen	N/A	N/A	DKX
Behrendt; Niels	Bagsvaerd	N/A	N/A	DKX
Ellis; Vincent	Copenhagen	N/A	N/A	DKX
H.o slashed.yer-Hansen; Gunilla	Gentofte	N/A	N/A	DKX
Pyke; Charles	S.o slashed.borg	N/A	N/A	DKX
Bruenner; Nils	Virum	N/A	N/A	DKX

US-CL-CURRENT: 424/130.1; 424/1.49, 424/145.1, 424/156.1, 424/158.1, 435/215, 435/217, 435/7.1, 530/358, 530/388.22, 530/388.24

ABSTRACT:

A monoclonal or polyclonal antibody directed against urokinase plasminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. Antibodies are disclosed which react with free u-PAR or with complexes between u-PA and u-PAR and which are capable of 1) catching u-PAR in ELISA, or 2) detecting u-PAR, e.g. in blotting, or 3) in radioimmunoprecipitation assay precipitate purified u-PAR in intact or fragment form, or 4) is useful for immunohistochemical detection of u-PAR, e.g. in immunostaining of cancer cells, such as in tissue sections at the invasive front, or 5) inhibits the binding of pro-u-PA and active u-PA and thereby inhibits cell surface plasminogen activation. Methods are disclosed 1) for detecting or quantifying u-PAR, 2) for targeting a diagnostic to a cell containing a u-PAR on the surface, 3) for preventing or counteracting proteolytic activity in a mammal. Methods for for selecting a substance suitable for inhibiting u-PA/u-PAR interaction, for preventing or counteracting localized proteolytical activity in a mammal, for inhibiting the invasion and/or metastasis comprise the use of the antibodies and of nude mice inoculated with human cancer cells which are known to invade and/or metastasize in mice and having a distinct color, f.x. obtained by means of an enzyme and a chromogenic substrate for the enzyme, the color being different from the cells of the mouse.

27 Claims, 61 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 35

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

20. Document ID: US 6103469 A

L9: Entry 20 of 53 File: USPT Aug 15, 2000

US-PAT-NO: 6103469
DOCUMENT-IDENTIFIER: US 6103469 A

TITLE: Human phospholipase A2 protein

DATE-ISSUED: August 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hawkins; Phillip R.	Mountain View	CA	N/A	N/A
Bandman; Olga	Mountain View	CA	N/A	N/A
Guegler; Karl J.	Menlo Park	CA	N/A	N/A
Shah; Purvi	Sunnyvale	CA	N/A	N/A
Corley; Neil C.	Mountain View	CA	N/A	N/A

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/91.2, 530/350, 536/22.1

ABSTRACT:

The invention provides a human phospholipase A2 protein PHPLA2 and polynucleotides which identify and encode PHPLA2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PHPLA2.

9 Claims, 3 Drawing figures Exemplary Claim Number: 1,4
Number of Drawing Sheets: 3

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw. Desc | Image

Generate Collection

Terms	Documents
l8 and (x-ray or crystal$10 or atomic coordinate$2)	53

Display 10 Documents, starting with Document: 21

Display Format: REV Change Format

WEST

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Generate Collection

Search Results - Record(s) 21 through 30 of 53 returned.

☐ 21. Document ID: US 6077954 A

L9: Entry 21 of 53 File: USPT Jun 20, 2000

US-PAT-NO: 6077954
DOCUMENT-IDENTIFIER: US 6077954 A

TITLE: Substituted heterocyclic compounds

DATE-ISSUED: June 20, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cook; P. Dan	Vista	CA	N/A	N/A
An; Haoyun	Encinitas	CA	N/A	N/A

US-CL-CURRENT: 544/353; 544/162, 544/182, 544/301, 544/333, 544/335, 544/336, 544/354, 544/405, 546/271.4, 546/272.4, 546/278.1, 546/334, 548/264.4, 548/267.8, 548/950, 548/967, 549/426, 549/492, 549/74, 549/75

ABSTRACT:

Novel compounds having the formula: ##STR1## wherein the constituent variables are defined herein. The compounds are constructed to include a central aromatic, aliphatic, or heterocyclic ring system. Attached to the central ring system are two linear groups having nitrogenous moieties that are derivatized with chemical functional groups. The ring system can include further nitrogenous moieties, either as ring atoms or on pendant groups attached to the ring, that may also be derivatized with chemical functional groups. The totality of the chemical functional groups imparts certain conformational and other properties to the these compounds. In accordance with certain embodiments of the invention, libraries of such compounds are prepared utilizing permutations and combinations of the chemical functional groups and the nitrogenous moieties to build complexity into the libraries.

16 Claims, 10 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw Desc | Image

☐ 22. Document ID: US 6054286 A

L9: Entry 22 of 53 File: USPT Apr 25, 2000

US-PAT-NO: 6054286
DOCUMENT-IDENTIFIER: US 6054286 A

TITLE: Methods to identify immunomodulators using cognate interaction of PKC-theta

DATE-ISSUED: April 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Villar; Hugo O.	Newark	CA	N/A	N/A
Patterson; John	Mountain View	CA	N/A	N/A
Voronova; Anna	Wayland	MA	N/A	N/A
Ron; Dorit	San Francisco	CA	N/A	N/A
Kauvar; Lawrence	San Francisco	CA	N/A	N/A
Napolitano; Gene	New York	NY	N/A	N/A
Vasquez; Nicki	San Francisco	CA	N/A	N/A

US-CL-CURRENT: 435/15; 435/975

ABSTRACT:

Compounds having immunomodulating activity are identified using a methodology which employs TER14687, TER10311 and/or TER17210 as standards. The effect candidate compounds have on PKC-theta interaction with cognate binding proteins is measured and compared with the standards. The interaction can be measured by a variety of techniques, including assessing translocation of said PKC-theta or fragment. Kits containing the TER14687, TER10311 and/or TER17210 standards are disclosed. TER14687, TER10311 and/or TER17210 are useful in modulating the immune system in a subject by reducing T-cell activity. TER14687, TER10311, TER17210 are used as leads to develop other compounds having immunomodulating activity.

9 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw. Desc | Image

☐ 23. Document ID: US 6025194 A

L9: Entry 23 of 53 File: USPT Feb 15, 2000

US-PAT-NO: 6025194
DOCUMENT-IDENTIFIER: US 6025194 A

TITLE: Nucleic acid sequence of senescence asssociated gene

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Funk; Walter	Hayward	CA	N/A	N/A

US-CL-CURRENT: 435/320.1; 435/325, 536/23.1, 536/23.5, 536/24.1

ABSTRACT:

Human gene GC6 is expressed more abundantly in senescent cells than young cells. Isolated, purified, and recombinant nucleic acids and proteins corresponding to the human GC6 gene and its mRNA and protein products, as well as peptides and antibodies corresponding to the GC6 protein can be used to identify senescent cells, distinguish between senescent and young cells, identify agents that alter senescent gene expression generally and GC6 expression specifically; such agents as well as GC6 gene and gene products and products corresponding thereto can be used to prevent and treat diseases and conditions relating to cell senescence.

10 Claims, 0 Drawing figures Exemplary Claim Number: 1,6

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 24. Document ID: US 6008344 A

L9: Entry 24 of 53 File: USPT Dec 28, 1999

US-PAT-NO: 6008344
DOCUMENT-IDENTIFIER: US 6008344 A

TITLE: Antisense modulation of phospholipase A2 group IV expression

DATE-ISSUED: December 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bennett; C. Frank	Carlsbad	CA	N/A	N/A
Cowsert; Lex M.	Carlsbad	CA	N/A	N/A

US-CL-CURRENT: 536/24.5; 435/325, 435/6, 435/91.1, 435/91.31, 536/23.1, 536/23.2, 536/24.3

ABSTRACT:

Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2 Group IV. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2 Group IV. Methods of using these compounds for modulation of Phospholipase A2 Group IV expression and for treatment of diseases associated with expression of Phospholipase A2 Group IV are provided.

20 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 25. Document ID: US 5919810 A

L9: Entry 25 of 53 File: USPT Jul 6, 1999

US-PAT-NO: 5919810
DOCUMENT-IDENTIFIER: US 5919810 A

TITLE: 1H-indole-3-glyoxylamide sPLA.sub.2 inhibitors

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bach; Nicholas J.	Indianapolis	IN	N/A	N/A
Dillard; Robert D.	Zionsville	IN	N/A	N/A
Draheim; Susan E.	Indianapolis	IN	N/A	N/A

US-CL-CURRENT: 514/419; 514/381, 544/373, 548/492, 548/494, 548/495

ABSTRACT:

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

29 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 26. Document ID: US 5919943 A

L9: Entry 26 of 53 File: USPT Jul 6, 1999

US-PAT-NO: 5919943
DOCUMENT-IDENTIFIER: US 5919943 A

TITLE: Process for preparing 1H-indole-3-glyoxylamides

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bach; Nicholas J.	Indianapolis	IN	N/A	N/A
Dillard; Robert D.	Zionsville	IN	N/A	N/A
Draheim; Susan E.	Indianapolis	IN	N/A	N/A

US-CL-CURRENT: 548/447; 548/492, 548/494

ABSTRACT:

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

3 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 27. Document ID: US 5908845 A

L9: Entry 27 of 53 File: USPT Jun 1, 1999

US-PAT-NO: 5908845
DOCUMENT-IDENTIFIER: US 5908845 A

TITLE: Polyether nucleic acids

DATE-ISSUED: June 1, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Segev; David	76804 Mazkeret Batya	N/A	N/A	ILX

US-CL-CURRENT: 514/261; 435/6, 514/269, 514/44, 514/885, 514/908, 536/23.1, 536/25.3, 536/25.31, 536/25.32, 536/25.4, 536/43, 536/44, 544/242, 544/264

ABSTRACT:

A compound comprising a polyether backbone bearing a plurality of ligands that are individually bound to chiral carbon atoms located within said backbone, at least one of said ligands including a moiety selected from the group consisting of a naturally occurring nucleobase, a nucleobase binding group and a DNA intercalator; a process of synthesizing the compound, monomers to be used in this process and their synthesis process and processes for using the compound in biochemistry and medicine.

17 Claims, 5 Drawing figures Exemplary Claim Number: 1,14
Number of Drawing Sheets: 4

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 28. Document ID: US 5886177 A

L9: Entry 28 of 53 File: USPT Mar 23, 1999

US-PAT-NO: 5886177
DOCUMENT-IDENTIFIER: US 5886177 A

TITLE: Phosphate linked oligomers

DATE-ISSUED: March 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cook; Phillip Dan	Vista	CA	N/A	N/A
Acevedo; Oscar L.	San Diego	CA	N/A	N/A
Davis; Peter W.	Carlsbad	CA	N/A	N/A
Ecker; David J.	Encinitas	CA	N/A	N/A
Hebert; Normand	Cardiff	CA	N/A	N/A

US-CL-CURRENT: 544/224; 435/6, 436/501, 530/300, 530/350, 536/22.1, 536/23.1, 536/24.1, 536/24.3, 536/24.31, 536/24.32, 536/24.33, 544/1, 544/232, 544/233, 544/235, 544/236, 544/238, 544/239

ABSTRACT:

Novel ethylene glycol compounds bearing various functional groups are used to prepare oligomeric structures. The ethylene glycol monomers can be joined via standard phosphate linkages including phosphorothioate, phosphodiester, and phosphoramidate linkages. Useful functional groups include nucleobases as well as polar groups, hydrophobic groups, ionic groups, aromatic groups and/or groups that participate in hydrogen-bonding.

22 Claims, 4 Drawing figures Exemplary Claim Number: 2
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw Desc | Image

☐ 29. Document ID: US 5760270 A

L9: Entry 29 of 53 File: USPT Jun 2, 1998

US-PAT-NO: 5760270
DOCUMENT-IDENTIFIER: US 5760270 A

TITLE: Process of producing ether-type thio-phospholipids

DATE-ISSUED: June 2, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ohtani; Mitsuaki	Nara	N/A	N/A	JPX
Fuji; Masahiro	Higashiosaka	N/A	N/A	JPX

US-CL-CURRENT: 558/87; 558/145, 558/169, 558/183

ABSTRACT:

A method of producing an ether-type thio-phospholipid of the formula (I): ##STR1## wherein: n is an integer of 13 to 17;

A is C.sub.14 -C.sub.20 acyl group;

G is a group selected from the group consisting of: ##STR2## which is useful as synthetic substrate of cytosolic phospholipase A.sub.2 inhibitors, said method being applicable to mass production of the compound (I), intermediates therefor and the preparation of the same are provided.

2 Claims, 0 Drawing figures Exemplary Claim Number: 1,2

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 30. Document ID: US 5756291 A

L9: Entry 30 of 53 File: USPT May 26, 1998

US-PAT-NO: 5756291
DOCUMENT-IDENTIFIER: US 5756291 A

TITLE: Aptamers specific for biomolecules and methods of making

DATE-ISSUED: May 26, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Griffin; Linda	Atherton	CA	N/A	N/A
Albrecht; Glenn	Redwood City	CA	N/A	N/A
Latham; John	Palo Alto	CA	N/A	N/A
Leung; Lawrence	Hillsborough	CA	N/A	N/A
Vermaas; Eric	Oakland	CA	N/A	N/A
Toole; John J.	Burlingame	CA	N/A	N/A

US-CL-CURRENT: 435/6; 530/413, 536/23.1

ABSTRACT:

A method for identifying oligomer sequences, optionally comprising modified base, which specifically bind target molecules such as serum proteins, kinins, eicosanoids and extracellular proteins is described. The method is used to generate aptamers that bind to serum Factor X, PDGF, FGF, ICAM, VCAM, E-selectin, thrombin, bradykinin, PGF2 and cell surface molecules. The technique involves complexation of the target molecule with a mixture of oligonucleotides containing random sequences and sequences which serve as primer for PCR under conditions wherein a complex is formed with the specifically binding sequences, but not with the other members of the oligonucleotide mixture. The complex is then separated from uncomplexed oligonucleotides and the complexed members of the oligonucleotide mixture are recovered from the separated complex using the polymerase chain reaction. The recovered oligonucleotides may be sequenced, and successive rounds of selection using complexation, separation, amplification and recovery can be employed. The oligonucleotides can be used for therapeutic and diagnostic purposes and for generating secondary aptamers.

12 Claims, 6 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 6

WEST

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Generate Collection

Search Results - Record(s) 31 through 40 of 53 returned.

☐ 31. Document ID: US 5733923 A

L9: Entry 31 of 53 File: USPT Mar 31, 1998

US-PAT-NO: 5733923
DOCUMENT-IDENTIFIER: US 5733923 A

TITLE: 1H-indole-3-glyoxylamide sPLA.sub.2 inhibitors

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bach; Nicholas J.	Indianapolis	IN	N/A	N/A
Dillard; Robert D.	Zionsville	IN	N/A	N/A
Draheim; Susan E.	Indianapolis	IN	N/A	N/A

US-CL-CURRENT: 514/419; 548/447, 548/494

ABSTRACT:

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

3 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 32. Document ID: US 5714606 A

L9: Entry 32 of 53 File: USPT Feb 3, 1998

US-PAT-NO: 5714606
DOCUMENT-IDENTIFIER: US 5714606 A

TITLE: Pyrrolidine-containing monomers and oligomers

DATE-ISSUED: February 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Acevedo; Oscar L.	San Diego	CA	N/A	N/A
Hebert; Normand	Cardiff	CA	N/A	N/A

US-CL-CURRENT: 544/243; 544/102, 544/104, 544/244, 544/262, 544/264, 544/267, 544/277, 544/299, 544/309, 544/311, 544/313, 544/314, 544/317, 544/335, 544/35, 548/112, 548/314.7, 548/361.1, 548/361.5, 548/362.1, 548/362.5, 548/364.1, 548/412, 548/413, 548/414, 548/440, 548/441, 548/443, 548/444, 548/446, 548/465, 548/466, 548/467, 548/518, 548/519, 548/523, 548/524, 548/530, 548/531, 548/542, 548/546

ABSTRACT:

The invention relates to pyrrolidine monomeric units and to oligomers which are joined via phosphate linkages, including phosphorothioate, phosphodiester and phosphoramidate linkages.

26 Claims, 1 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 33. Document ID: US 5684034 A

L9: Entry 33 of 53 File: USPT Nov 4, 1997

US-PAT-NO: 5684034
DOCUMENT-IDENTIFIER: US 5684034 A

TITLE: 1H-indole-3-acetamide sPLA.sub.2 inhibitors

DATE-ISSUED: November 4, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bach; Nicholas J.	Indianapolis	IN	N/A	N/A
Dillard; Robert D.	Zionsville	IN	N/A	N/A
Draheim; Susan E.	Indianapolis	IN	N/A	N/A
Hermann; Robert B.	Indianapolis	IN	N/A	N/A
Schevitz; Richard W.	Indianapolis	IN	N/A	N/A

US-CL-CURRENT: 514/419; 514/418, 548/113, 548/483, 548/486, 548/493, 548/496

ABSTRACT:

A class of novel 1-indole-3-acetamides represented by the formula; ##STR1## is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids.

18 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 34. Document ID: US 5663405 A

L9: Entry 34 of 53 File: USPT Sep 2, 1997

US-PAT-NO: 5663405
DOCUMENT-IDENTIFIER: US 5663405 A

TITLE: Process of producing ether-type thio-phospholipids

DATE-ISSUED: September 2, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ohtani; Mitsuaki	Nara	N/A	N/A	JPX
Fuji; Masahiro	Higashiosaka	N/A	N/A	JPX

US-CL-CURRENT: 558/166; 558/169, 558/183, 558/194, 558/84

ABSTRACT:

A method of producing an ether-type thio-phospholipid of the formula (I): ##STR1## wherein: n is an integer of 13 to 17;

A is C.sub.14 -C.sub.20 acyl group;

G is a group selected from the group consisting of: ##STR2## which is useful as synthetic substrate of cytosolic phospholipase A.sub.2 inhibitors, said method being applicable to mass production of the compound (I), intermediates therefor and the preparation of the same are provided.

5 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 35. Document ID: US 5654326 A

L9: Entry 35 of 53 File: USPT Aug 5, 1997

US-PAT-NO: 5654326
DOCUMENT-IDENTIFIER: US 5654326 A

TITLE: 1H-indole-3-glyoxylamide SPLA.sub.2 inhibitors

DATE-ISSUED: August 5, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bach; Nicholas J.	Indianapolis	IN	N/A	N/A
Dillard; Robert D.	Zionsville	IN	N/A	N/A
Draheim; Susan E.	Indianapolis	IN	N/A	N/A

US-CL-CURRENT: 514/419; 514/381, 544/373, 548/492, 548/494, 548/495

ABSTRACT:

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

28 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 36. Document ID: US 5646254 A

L9: Entry 36 of 53 File: USPT Jul 8, 1997

US-PAT-NO: 5646254
DOCUMENT-IDENTIFIER: US 5646254 A

TITLE: Antibodies for human phospholipase inhibitory protein (hPIP)

DATE-ISSUED: July 8, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Lorin K.	Pleasanton	CA	N/A	N/A
Longenecker; John P.	Mountain View	CA	N/A	N/A

US-CL-CURRENT: 530/388.85; 530/387.1, 530/388.26, 530/389.1

ABSTRACT:

Antibodies which react with the human phospholipase inhibitory protein/apolipoprotein AIV complex and hPIP are provided.

2 Claims, 25 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 19

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 37. Document ID: US 5641800 A

L9: Entry 37 of 53 File: USPT Jun 24, 1997

US-PAT-NO: 5641800
DOCUMENT-IDENTIFIER: US 5641800 A

TITLE: 1H-indole-1-functional sPLA.sub.2 inhibitors

DATE-ISSUED: June 24, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bach; Nicholas J.	Indianapolis	IN	N/A	N/A
Dillard; Robert D.	Zionsville	IN	N/A	N/A
Draheim; Susan E.	Indianopolis	IN	N/A	N/A

US-CL-CURRENT: 514/415; 514/91, 548/113, 548/481

ABSTRACT:

A class of novel 1H-indole-1-functional compounds is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock. The compounds are 1H-indole-1-acetamides, 1H-indole-1-acetic acid hydrazides, and 1H-indole-1-glyoxylamides.

21 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw. Desc | Image

☐ 38. Document ID: US 5641755 A

L9: Entry 38 of 53 File: USPT Jun 24, 1997

US-PAT-NO: 5641755
DOCUMENT-IDENTIFIER: US 5641755 A

TITLE: Regulation of x-ray mediated gene expression

DATE-ISSUED: June 24, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weichselbaum; Ralph R.	Chicago	IL	N/A	N/A
Hallahan; Dennis E.	Park Ridge	IL	N/A	N/A
Kufe; Donald W.	Wellesley	MA	N/A	N/A

US-CL-CURRENT: 514/44; 424/9.2, 435/29, 435/6, 514/396, 536/24.1

ABSTRACT:

Treatment of cells with ionizing radiation is associated with the production of arachidonic acid. Inhibition of phospholipase A2 abolishes radiation-mediated arachidonate production, protein kinase C induction and tumor necrosis factor gene expression. The addition of inhibitors of lipoxygenase, such as ketoconazole, prior to irradiation reduces the expression of of tumor necrosis factor while maintaining the expression of other radiation inducible genes, such as Egr-1 and c-jun. In contrast, indomethacin, an inhibitor of cyclooxygenase, enhanced the expression of tumor necrosis factor as well as other radiation inducible genes. The results show that lipoxygenase inhibitors are useful in the treatment of radiation-induced mucositis, dermatitis, pneumonitis, proctitis, and esophagitis. which may be due to the production of cytokines such as TNF.

4 Claims, 5 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw. Desc | Image

☐ 39. Document ID: US 5622828 A

L9: Entry 39 of 53 File: USPT Apr 22, 1997

US-PAT-NO: 5622828
DOCUMENT-IDENTIFIER: US 5622828 A

TITLE: High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA.sub.2)

DATE-ISSUED: April 22, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Parma; David H.	Boulder	CO	N/A	N/A
Gold; Larry	Boulder	CO	N/A	N/A

US-CL-CURRENT: 435/6; 435/91.2, 536/22.1

ABSTRACT:

This invention discloses high-affinity oligonucleotide ligands to human secretory phospholipase A2 (sPLA.sub.2), specifically RNA ligands having the ability to bind to sPLA.sub.2, and the methods for obtaining such ligands.

11 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 40. Document ID: US 5607691 A

L9: Entry 40 of 53 File: USPT Mar 4, 1997

US-PAT-NO: 5607691
DOCUMENT-IDENTIFIER: US 5607691 A

TITLE: Compositions and methods for enhanced drug delivery

DATE-ISSUED: March 4, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hale; Ron L.	Woodside	CA	N/A	N/A
Lu; Amy	Los Altos	CA	N/A	N/A
Solas; Dennis	San Francisco	CA	N/A	N/A
Selick; Harold E.	Belmont	CA	N/A	N/A
Oldenburg; Kevin R.	Fremont	CA	N/A	N/A
Zaffaroni; Alejandro C.	Atherton	CA	N/A	N/A

US-CL-CURRENT: 424/449; 514/1, 514/169, 514/183, 514/2, 514/26, 514/553, 514/556, 604/20

ABSTRACT:

The present invention relates to methods of delivering pharmaceutical agents across membranes, including the skin layer or mucosal membranes of a patient. A pharmaceutical agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.

5 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

Generate Collection

Terms	Documents
l8 and (x-ray or crystal$10 or atomic coordinate$2)	53

Display 10 Documents, starting with Document: 41

Display Format: REV Change Format

WEST

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Generate Collection

Search Results - Record(s) 41 through 50 of 53 returned.

☐ 41. Document ID: US 5597719 A

L9: Entry 41 of 53 File: USPT Jan 28, 1997

US-PAT-NO: 5597719
DOCUMENT-IDENTIFIER: US 5597719 A

TITLE: Interaction of RAF-1 and 14-3-3 proteins

DATE-ISSUED: January 28, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Freed; Ellen	Oakland	CA	N/A	N/A
Ruggieri; Rosamaria	San Francisco	CA	N/A	N/A

US-CL-CURRENT: 435/194

ABSTRACT:

Intermolecular interactions between Raf-1 and human 14-3-3 proteins which regulate Raf activity are identified. Compositions and method for identifying novel drugs which modulate Raf activity in vivo are provided.

6 Claims, 16 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 14

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw. Desc | Image

☐ 42. Document ID: US 5552530 A

L9: Entry 42 of 53 File: USPT Sep 3, 1996

US-PAT-NO: 5552530
DOCUMENT-IDENTIFIER: US 5552530 A

TITLE: Antibodies that specifically bind to and inhibit human synovial phospholipase A.sub.2 type A

DATE-ISSUED: September 3, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Lorin K.	Pleasanton	CA	N/A	N/A
Seilhamer; Jeffrey J.	Milpitas	CA	N/A	N/A
Pruzanski; Waldemar	Willowdale	N/A	N/A	CAX
Vadas; Peter	Toronto	N/A	N/A	CAX

US-CL-CURRENT: 530/387.9; 530/388.26, 530/389.1

ABSTRACT:

Antibodies that specifically bind to and inhibit the enzymatic activity of synovial phospholipase A.sub.2 Type A are described. The antibodies may be used in assays for detection of synovial phospholipase A.sub.2 in biological samples.

8 Claims, 18 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 43. Document ID: US 5373095 A

L9: Entry 43 of 53 File: USPT Dec 13, 1994

US-PAT-NO: 5373095
DOCUMENT-IDENTIFIER: US 5373095 A

TITLE: Steroid compounds

DATE-ISSUED: December 13, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Roy A.	Kalamazoo	MI	N/A	N/A
Bundy; Gordon L.	Portage	MI	N/A	N/A
Youngdale; Gilbert A.	Portage	MI	N/A	N/A
Morton; Douglas R.	Portage	MI	N/A	N/A
Wallach, deceased; Donald P.	late of Richland	MI	N/A	N/A

US-CL-CURRENT: 540/95; 540/106

ABSTRACT:

Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.

2 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 44. Document ID: US 5342764 A

L9: Entry 44 of 53 File: USPT Aug 30, 1994

US-PAT-NO: 5342764
DOCUMENT-IDENTIFIER: US 5342764 A

TITLE: Recombinant expression system for human anti-inflammatory phospholipase inhibitor protein

DATE-ISSUED: August 30, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Lorin K.	Pleasanton	CA	N/A	N/A
Longenecker; John P.	Mountain View	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 536/23.5

ABSTRACT:

Cloning and expression of the gene encoding human phospholipase inhibitory protein (hPIP) permits production of an anti-inflammatory protein in practical quantities using recombinant techniques.

8 Claims, 29 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 20

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw. Desc | Image

☐ 45. Document ID: US 5334712 A

L9: Entry 45 of 53 File: USPT Aug 2, 1994

US-PAT-NO: 5334712
DOCUMENT-IDENTIFIER: US 5334712 A

TITLE: Cyclic hydrocarbons with an aminoalkyl sidechain

DATE-ISSUED: August 2, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Roy A.	Kalamazoo	MI	N/A	N/A
Bundy; Gordon L.	Portage	MI	N/A	N/A
Youngdale; Gilbert A.	Portage	MI	N/A	N/A
Morton; Douglas R.	Portage	MI	N/A	N/A
Wallach, deceased; Donald P.	late of Richland	MI	N/A	N/A

US-CL-CURRENT: 540/112; 540/117, 552/522

ABSTRACT:

Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.

5 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 46. Document ID: US 5274089 A

L9: Entry 46 of 53 File: USPT Dec 28, 1993

US-PAT-NO: 5274089
DOCUMENT-IDENTIFIER: US 5274089 A

TITLE: Cyclic hydrocarbons with an aminoalkyl sidechain

DATE-ISSUED: December 28, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bundy; Gordon L.	Kalamazoo	MI	N/A	N/A
Wallach, deceased; Donald P.	late of Richland	MI	N/A	N/A

US-CL-CURRENT: 540/112; 552/522

ABSTRACT:

Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.

3 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 47. Document ID: US 5264550 A

L9: Entry 47 of 53 File: USPT Nov 23, 1993

US-PAT-NO: 5264550
DOCUMENT-IDENTIFIER: US 5264550 A

TITLE: Human anti-inflammatory phospholipase inhibitor protein

DATE-ISSUED: November 23, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Lorin K.	Pleasanton	CA	N/A	N/A
Longenecker; John P.	Mt. View	CA	N/A	N/A

US-CL-CURRENT: 530/350; 435/69.2, 530/395, 530/851

ABSTRACT:

Cloning and expression of the gene encoding human phosphlipase inhibitory protein (hPIP) permits production of an anti-inflammatory protein in practical quantities using recombinant techniques.

6 Claims, 29 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 20

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 48. Document ID: US 5196542 A

L9: Entry 48 of 53 File: USPT Mar 23, 1993

US-PAT-NO: 5196542
DOCUMENT-IDENTIFIER: US 5196542 A

TITLE: Cyclic hydrocarbons with an aminoalkyl sidechain

DATE-ISSUED: March 23, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Roy A.	Kalamazoo	MI	N/A	N/A
Bundy; Gordon L.	Portage	MI	N/A	N/A
Youngdale; Gilbert A.	Portage	MI	N/A	N/A
Morton; Douglas R.	Portage	MI	N/A	N/A
Wallach, deceased; Donald P.	late of Richland	MI	N/A	N/A

US-CL-CURRENT: 546/326; 540/107, 546/333, 564/460

ABSTRACT:

Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.

3 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 49. Document ID: US 5187299 A

L9: Entry 49 of 53 File: USPT Feb 16, 1993

US-PAT-NO: 5187299
DOCUMENT-IDENTIFIER: US 5187299 A

TITLE: Cyclic hydrocarbons with an aminoalkyl sidechain

DATE-ISSUED: February 16, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Roy A.	Kalamazoo	MI	N/A	N/A
Bundy; Gordon L.	Portage	MI	N/A	N/A
Youngdale; Gilbert A.	Portage	MI	N/A	N/A
Morton; Douglas R.	Portage	MI	N/A	N/A
Wallach, deceased; Donald P.	late of Portage	MI	N/A	N/A
Wallach, Legal Representative, by Vera M.	Richland	MI	N/A	N/A

US-CL-CURRENT: 552/522; 552/554

ABSTRACT:

Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain.

5 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference

KWIC | Draw Desc | Image

☐ 50. Document ID: US 5145874 A

L9: Entry 50 of 53 File: USPT Sep 8, 1992

US-PAT-NO: 5145874
DOCUMENT-IDENTIFIER: US 5145874 A

TITLE: Cyclic hydrocarbons with an aminoalkyl sidechain

DATE-ISSUED: September 8, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Roy A.	Kalamazoo	MI	N/A	N/A
Bundy; Gordon L.	Portage	MI	N/A	N/A
Youngdale; Gilbert A.	Portage	MI	N/A	N/A
Morton; Douglas R.	Portage	MI	N/A	N/A
Wallach, deceased; Donald P.	late of Kalamazoo	MI	N/A	N/A
Wallach, legal representative; by Vera M.	Richland	MI	N/A	N/A

US-CL-CURRENT: 514/650; 514/529, 514/532, 514/533, 514/534, 514/538, 514/545, 514/579, 514/613, 514/616, 514/617, 514/618, 514/619, 514/620, 514/621, 514/622, 514/623, 514/642, 564/281, 564/337, 564/453, 564/454, 564/455, 564/456, 564/461

ABSTRACT:

Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.

8 Claims, 0 Drawing figures Exemplary Claim Number: 1

WEST

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Generate Collection

Search Results - Record(s) 51 through 53 of 53 returned.

☐ 51. Document ID: US 5001234 A

L9: Entry 51 of 53 File: USPT Mar 19, 1991

US-PAT-NO: 5001234
DOCUMENT-IDENTIFIER: US 5001234 A

TITLE: Cyclic hydrocarbons with an aminoalkyl sidechain

DATE-ISSUED: March 19, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bundy; Gordon L.	Portage	N/A	N/A	N/A
Youngdale; Gilbert A.	Portage	MI	N/A	N/A

US-CL-CURRENT: 540/106; 552/521

ABSTRACT:

This invention provides novel cyclic hydrocarbons of the formula: ##STR1## wherein R is selected from the group consisting of CH.sub.2 .dbd.CH--CH.sub.2 --, HO--CH.sub.2 CH.sub.2 CH.sub.2 --, and CH.sub.3 ;

wherein R.sub.1 is selected from the group consisting of m-trifluoromethylphenylmethyl, 2-thienylmethyl, and p-aminosulfonylphenylethyl;

wherein R.sub.2 and R.sub.3 are methyl or hydrogen;

wherein R.sub.4 is hydrogen or --OH;

a compound of the formula ##STR2## wherein R is (CH.sub.3).sub.2 NCH.sub.2 CH.sub.2 CH.sub.2 -- or NH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 --;

or a compound of the formula ##STR3## wherein the dashed line indicates that the 2-3 bond is saturated or unsaturated and, wherein R is hydrogen or methyl.

These compounds are useful for inhibiting adverse physiological symptoms associated with phospholipase A.sub.2 and for treating hyperglycemia associated diseases such as diabetes and obesity.

6 Claims, 0 Drawing figures Exemplary Claim Number: 1,3,5

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWMC | Draw Desc | Image

☐ 52. Document ID: US 4917826 A

L9: Entry 52 of 53 File: USPT Apr 17, 1990

US-PAT-NO: 4917826
DOCUMENT-IDENTIFIER: US 4917826 A

TITLE: Cyclic hydrocarbons with an aminoalkyl sidechain

DATE-ISSUED: April 17, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Roy A.	Kalamazoo	MI	N/A	N/A
Bundy; Gordon L.	Portage	MI	N/A	N/A
Youngdale; Gilbert A.	Portage	MI	N/A	N/A
Morton; Douglas R.	Portage	MI	N/A	N/A
Wallach, deceased; Donald P.	late of Kalamazoo	MI	N/A	N/A

US-CL-CURRENT: 552/522; 514/169, 514/182, 514/237.8, 514/253.02, 514/351, 514/352, 514/381, 514/398, 514/399, 514/400, 514/424, 514/426, 514/471, 514/472, 514/866, 544/154, 544/380, 546/300, 546/304, 546/307, 546/312

ABSTRACT:

Provided are cyclic hydrocarbons of Formula I ##STR1## with an aminoalkyl sidechain that are useful for treating phospholipase A2 mediated conditions, diabetes, and obesity.

3 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference KWIC | Draw Desc | Image

☐ 53. Document ID: HU 200000292 A2, EP 846687 A1, WO 9824437 A1, AU 9853655 A, ZA 9710878 A, US 5972972 A, BR 9713993 A, MX 9905167 A1, KR 2000057366 A

L9: Entry 53 of 53 File: DWPI Apr 28, 2001

DERWENT-ACC-NO: 1998-299930
DERWENT-WEEK: 200131
COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: New pyrazole derivatives used to treat e.g. septic shock - are human non-pancreatic secretory phospholipase A2 inhibitors, and inhibit mediated release of fatty acids and arachidonic acid cascade

INVENTOR: DOMAN, P J; HITE, G A ; MIHELICH, E D ; SUAREZ, T ; WILLETTS, S E ; MICHELICH, E D

PRIORITY-DATA: 1996US-0033216 (December 4, 1996), 1997US-0984261 (December 3, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
HU 200000292 A2	April 28, 2001	N/A	000	A61K031/495
EP 846687 A1	June 10, 1998	E	044	C07D231/44
WO 9824437 A1	June 11, 1998	E	000	A61K031/495
AU 9853655 A	June 29, 1998	N/A	000	A61K031/495
ZA 9710878 A	August 31, 1999	N/A	078	C07D000/00
US 5972972 A	October 26, 1999	N/A	000	C07D401/04
BR 9713993 A	February 8, 2000	N/A	000	A61K031/495
MX 9905167 A1	October 1, 1999	N/A	000	A61K031/495
KR 2000057366 A	September 15, 2000	N/A	000	C07D231/00

INT-CL (IPC): A61K 31/415; A61K 31/44; A61K 31/47; A61K 31/495; A61K 31/50; A61P 37/00; C07D 0/00; C07D 231/00; C07D 231/44; C07D 231/52; C07D 401/04; C07D 401/14; C07D 403/00; C07D 403/04; C07D 405/00; C07D 409/00; C07D 409/12; C07D 409/14; C07D 417/14; C07D 213/00; C07D 401/04

ABSTRACTED-PUB-NO: EP 846687A
BASIC-ABSTRACT:

Pyrazole derivatives of formula (I) and their salts are new: R1 = Ph, isoquinolin-3-yl, pyrazinyl, pyridin-2-yl (optionally 4-substituted by 1-4C alkyl, 1-4C alkoxy, CN or (CH2)nCONH2; n = 0-2; R2 = Ph (optionally substituted by 1-3 1-4C alkyl, CN, halo, NO2, CO2(1-4C) alkyl or CF3), naphthyl or thiophene (optionally substituted by 1-3 halo); R3 = H, Ph, phenyl(2-6C) alkenyl, pyridyl, naphthyl, quinolinyl, 1-4C alkylthioazolyl or Ph (optionally substituted by 1-2 1-4C alkyl, CN, CONH2, NO2, CF3, halo, 1-4C alkoxy, CO2(1-4C) alkyl, OPh or SR4 or by one O(CH2)pR5, Ph or OR6, or by two substituents which form methylene dioxy; R4 = 1-4C alkyl or halophenyl; p = 1-3; R5 = CN, COOH, CONH2 or tetrazolyl; R6 = cyclopentyl, cyclohexenyl or Ph (substituted by halo or 1-4C alkoxy); and m = 1-5.

USE - (I) are human non-pancreatic secretory phospholipase A2 inhibitors (sPLA2) and are useful for alleviating the pathological effects of septic shock, adult respiratory syndrome (ARDS), pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, rheumatoid arthritis, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondylarthropathies, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enterapathric spondylitis, Juvenile arthropathy or juvenile ankylosing spondylitis, Reactive arthropathy, infectious or post-infections arthritis, gonoccocal arthritis, Tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with vasculitic syndrome, polyarteritis nodosa, hypersensitivity vasculitis, Luegenec's granulomatosis, polymyalgia, rheumatica, joint cell arteritis, calcium crystal deposition arthropathies, pseudo gout, non-articular rheumatism, bursitis, tenosynomitis, epicondylitis, carpal tunnel syndrome, repetitive use injury, miscellaneous forms of arthritis, neuropathic joint disease, haemarthrosis, Henoch-Schonlein Purpura, hypertrophic osteoarthropathy, multicentre reticulohistocytosis, arthritis associated with certain diseases, surcoilosis, haemochromatosis, sickle cell disease and other haemoglobinopathies, hyperlipoproteinaemia, hypogammaglobulinaemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behat's disease, systemic lupus erythematosis or relapsing polychondritis (claimed). (I) inhibit sPLA2 mediated release of fatty acids and inhibits or prevents arachidonic acid cascade and its deleterious products.
ABSTRACTED-PUB-NO:

US 5972972A EQUIVALENT-ABSTRACTS:

Pyrazole derivatives of formula (I) and their salts are new: R1 = Ph, isoquinolin-3-yl, pyrazinyl, pyridin-2-yl (optionally 4-substituted by 1-4C alkyl, 1-4C alkoxy, CN or (CH2)nCONH2; n = 0-2; R2 = Ph (optionally substituted by 1-3 1-4C alkyl, CN, halo, NO2, CO2(1-4C) alkyl or CF3), naphthyl or thiophene (optionally substituted by 1-3 halo); R3 = H, Ph, phenyl(2-6C) alkenyl, pyridyl, naphthyl, quinolinyl, 1-4C alkylthioazolyl or Ph (optionally substituted by 1-2 1-4C alkyl, CN, CONH2, NO2, CF3, halo, 1-4C alkoxy, CO2(1-4C) alkyl, OPh or SR4 or by one O(CH2)pR5, Ph or OR6, or by two substituents which form methylene dioxy; R4

= 1-4C alkyl or halophenyl; p = 1-3; R5 = CN, COOH, CONH2 or tetrazolyl; R6 = cyclopentyl, cyclohexenyl or Ph (substituted by halo or 1-4C alkoxy); and m = 1-5.

USE - (I) are human non-pancreatic secretory phospholipase A2 inhibitors (sPLA2) and are useful for alleviating the pathological effects of septic shock, adult respiratory syndrome (ARDS), pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, rheumatoid arthritis, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondylarthropathies, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enterapathric spondylitis, Juvenile arthropathy or juvenile ankylosing spondylitis, Reactive arthropathy, infectious or post-infections arthritis, gonoccocal arthritis, Tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with vasculitic syndrome, polyarteritis nodosa, hypersensitivity vasculitis, Luegenec's granulomatosis, polymyalgia, rheumatica, joint cell arteritis, calcium crystal deposition arthropathies, pseudo gout, non-articular rheumatism, bursitis, tenosynomitis, epicondylitis, carpal tunnel syndrome, repetitive use injury, miscellaneous forms of arthritis, neuropathic joint disease, haemarthrosis, Henoch-Schonlein Purpura, hypertrophic osteoarthropathy, multicentre reticulohistocytosis, arthritis associated with certain diseases, surcoilosis, haemochromatosis, sickle cell disease and other haemoglobinopathies, hyperlipoproteinaemia, hypogammaglobulinaemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behat's disease, systemic lupus erythematosis or relapsing polychondritis (claimed). (I) inhibit sPLA2 mediated release of fatty acids and inhibits or prevents arachidonic acid cascade and its deleterious products.